Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12209130 | 1.00 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4HRH3 | |
| SCHEMBL17694861 | 0.89 | HRH3 (0.33) | HRH3 | |
| SCHEMBL19558161 | 0.88 | HTR2C (0.31) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL10360439 | 0.86 | GNAI3 (0.33) | HRH3 | |
| SCHEMBL10360894 | 0.86 | HRH3 (0.31) | HRH3 | |
| SCHEMBL12250822 | 0.84 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL27380454 | 0.84 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL22827192 | 0.84 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL14224176 | 0.84 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL19756453 | 0.84 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981875-B2 | Quinolone-based compounds with anticancer activity | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200071273-A1 | QUINOLONE-BASED COMPOUNDS WITH ANTICANCER ACTIVITY | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071273-A1 | QUINOLONE-BASED COMPOUNDS WITH ANTICANCER ACTIVITY | TOP2A, TOP2B, TOP1 | CHRNB2 4275/4885CHRNB4 4156/4885CHRNA3 4319/4885 |
| US-10981875-B2 | Quinolone-based compounds with anticancer activity | TOP2A, TOP2B, TOP1 | CHRNB2 4275/4885CHRNB4 4156/4885CHRNA3 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.